Protein Summary
Functions as a GC-rich promoter-specific transactivating transcription factor. This gene was originally isolated by subtractive hybridization of cDNAs expressed in atherosclerotic plaques with a thrombus, and was found to be expressed only in vascular smooth muscle cells. However, a shorter splice variant was found to be more ubiquitously expressed. This protein is suggested to play a role in the development of atherosclerosis. Studies in mice suggest that it may also function as a GC-rich promoter-specific trans-activating transcription factor. Several alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Feb 2011]
- ENST00000264779
- ENSP00000264779
- ENSG00000062194
- ENST00000506184
- ENSP00000421202
- ENST00000511209
- ENSP00000422337
- ENST00000514387
- ENSP00000421709
- GPBP
- SSH6
- GPBP
- SSH6
- VASCULIN
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 1 | ||
transcription factor | 0.95 | ||
transcription factor binding site profile | 0.86 | ||
kinase perturbation | 0.76 | ||
tissue sample | 0.72 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5.97 (req: < 5)
Gene RIFs: 3 (req: <= 3)
Antibodies: 82 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5.97 (req: >= 5)
Gene RIFs: 3 (req: > 3)
Antibodies: 82 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0